ASCO 2020: Overall survival benefit from secondary cytoreductive surgery, and results from SOLO-2 and FORWARD II for recurrent ovarian cancer

DESKTOP III study results could be practice-changing in recurrent ovarian cancer. Credit: Shutterstock



  • asco 2020 trials